OmicsBank, a clinical data infrastructure company connecting fragmented hospital data for drug development and healthcare AI, today announced $2.25 million in seed funding from global venture capital and technology firm Redesign Health. The investment will support U.S. expansion across health systems, pharmaceutical and biotechnology companies, CROs, and AI developers, while growing its clinical data network across Asia and the Middle East.

OmicsBank is a clinical data infrastructure company. Its platform is deployed within hospital and diagnostic networks across South Asia, Southeast Asia, and the Middle East, turning fragmented, unstructured clinical records into standardized, de-identified, patient-level datasets that research and AI systems can query directly. Its offering spans FHIR, OMOP CDM-structured EHR data, imaging, and genomic, transcriptomic, proteomic, phenomic, and metabolomic datasets and biospecimens - all made available under IRB and ethics committee approval, through an ISO 27001-certified, HIPAA- and GDPR-compliant process. OmicsBank works with pharma companies and frontier AI labs on drug discovery, drug development, and clinical AI.